Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLTNASDAQ:FBIONASDAQ:RGLSNASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$0.37+4.2%$0.38$0.30▼$1.34$14.19M0.96174,043 shs94,966 shsFBIOFortress Biotech$1.69-1.7%$1.62$1.33▼$2.89$49.97M1.85405,482 shs161,975 shsRGLSRegulus Therapeutics$7.85$2.63$0.83▼$8.20$520.01M0.49870,934 shs696,175 shsVSTMVerastem$6.94+3.7%$6.33$2.10▼$13.52$357.34M0.851.05 million shs3.52 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics+4.23%+5.41%+19.35%-23.30%-66.67%FBIOFortress Biotech-2.03%-3.43%+18.18%-5.32%-3.43%RGLSRegulus Therapeutics0.00%0.00%+390.63%+559.66%+245.81%VSTMVerastem+3.80%-6.59%+49.57%+19.86%-39.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOLTBolt Biotherapeutics2.2523 of 5 stars3.03.00.00.01.81.71.3FBIOFortress Biotech1.485 of 5 stars3.50.00.00.00.03.30.6RGLSRegulus Therapeutics1.593 of 5 stars2.15.00.00.02.51.70.0VSTMVerastem3.141 of 5 stars4.51.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.00Hold$1.13204.05% UpsideFBIOFortress Biotech 3.00Buy$21.001,142.60% UpsideRGLSRegulus Therapeutics 2.29Hold$8.508.28% UpsideVSTMVerastem 3.00Buy$13.89100.13% UpsideCurrent Analyst Ratings BreakdownLatest FBIO, VSTM, BOLT, and RGLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$9.004/30/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2025RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2025RGLSRegulus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$7.004/30/2025RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$28.00 ➝ $11.004/30/2025RGLSRegulus TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $7.004/10/2025VSTMVerastemJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/9/2025VSTMVerastemMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.003/27/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$3.00 ➝ $6.003/25/2025BOLTBolt BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/25/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.50 ➝ $1.25(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.84N/AN/A$2.97 per share0.12FBIOFortress Biotech$57.68M0.87N/AN/A$0.10 per share16.90RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/AVSTMVerastem$10M35.73N/AN/A$2.27 per share3.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$69.20M-$1.66N/AN/AN/A-665.56%-69.46%-48.55%5/13/2025 (Estimated)FBIOFortress Biotech-$60.64M-$2.78N/AN/AN/A-84.53%N/A-34.93%5/13/2025 (Estimated)RGLSRegulus Therapeutics-$30.04M-$0.87N/AN/AN/AN/A-53.07%-48.58%N/AVSTMVerastem-$87.37M-$3.50N/AN/AN/AN/A-332.73%-73.97%N/ALatest FBIO, VSTM, BOLT, and RGLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025FBIOFortress Biotech-$0.44N/AN/AN/A$11.62 millionN/A5/13/2025Q1 2025BOLTBolt Biotherapeutics-$0.34N/AN/AN/A$0.77 millionN/A5/8/2025Q1 2025RGLSRegulus Therapeutics-$0.33-$0.15+$0.18-$0.15N/AN/A3/31/2025Q4 2024FBIOFortress Biotech-$0.79-$0.26+$0.53-$0.26$16.30 million$15.12 million3/24/2025Q4 2024BOLTBolt Biotherapeutics-$0.38-$0.38N/A-$0.42$0.79 million$0.01 million3/20/2025Q4 2024RGLSRegulus Therapeutics-$0.20-$0.20N/A-$0.20N/AN/A3/20/2025Q4 2024VSTMVerastem-$0.76-$1.33-$0.57-$1.33$0.15 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt Biotherapeutics$0.3697.30%N/AN/A N/AFBIOFortress BiotechN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.213.163.16FBIOFortress BiotechN/A1.231.06RGLSRegulus TherapeuticsN/A14.1514.14VSTMVerastem2.773.233.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%FBIOFortress Biotech96.51%RGLSRegulus Therapeutics92.38%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics6.10%FBIOFortress Biotech33.40%RGLSRegulus Therapeutics4.35%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics9038.34 million26.45 millionNot OptionableFBIOFortress Biotech17029.57 million18.39 millionOptionableRGLSRegulus Therapeutics3066.24 million62.65 millionOptionableVSTMVerastem5051.49 million43.53 millionOptionableFBIO, VSTM, BOLT, and RGLS HeadlinesRecent News About These CompaniesVerastem Ovarian-Cancer Drug Combination Gets FDA Approval -- UpdateMay 8 at 9:03 PM | marketwatch.comFDA Approves Verastem's Avmapki, Fakzynja Combo for KRAS-Mutant Ovarian Cancer PatientsMay 8 at 9:03 PM | precisionmedicineonline.comVerastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s PleasedMay 8 at 9:03 PM | msn.comFDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian CancerMay 8 at 3:18 PM | benzinga.comVerastem’s Breakthrough FDA Approval and Market Potential for KRAS Mutant LGSOC TherapyMay 8 at 2:18 PM | tipranks.comFDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian CancerMay 8 at 1:17 PM | businesswire.comU.S. FDA approves Verastem's cancer therapyMay 8 at 12:23 PM | reuters.comSusquehanna Fundamental Investments LLC Buys New Shares in Verastem, Inc. (NASDAQ:VSTM)May 7 at 4:19 AM | marketbeat.comVerastem, Inc. (NASDAQ:VSTM) Holdings Boosted by BVF Inc. ILMay 6 at 7:31 AM | marketbeat.comB. Riley Has Pessimistic Outlook of Verastem Q2 EarningsMay 3, 2025 | marketbeat.comVerastem (VSTM) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comB. Riley Has Optimistic Outlook of Verastem FY2029 EarningsMay 2, 2025 | marketbeat.comVerastem Oncology to Present at Upcoming Investor ConferencesMay 2, 2025 | finance.yahoo.comB. Riley Issues Negative Forecast for Verastem EarningsMay 2, 2025 | americanbankingnews.comVerastem, Inc. (NASDAQ:VSTM) Shares Bought by Geode Capital Management LLCApril 28, 2025 | marketbeat.comMarshall Wace LLP Invests $4.10 Million in Verastem, Inc. (NASDAQ:VSTM)April 27, 2025 | marketbeat.comVerastem Oncology Announces $75 million Private Placement | VSTM Stock NewsApril 25, 2025 | gurufocus.comVerastem Oncology Announces $75 million Private PlacementApril 25, 2025 | gurufocus.comVerastem Oncology Announces $75 million Private PlacementApril 25, 2025 | finance.yahoo.comVerastem Oncology rises on $75M private placementApril 25, 2025 | seekingalpha.comVerastem announces U.S. IND clearance of VS-7375April 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBIO, VSTM, BOLT, and RGLS Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$0.37 +0.02 (+4.23%) Closing price 05/8/2025 04:00 PM EasternExtended Trading$0.37 0.00 (0.00%) As of 05/8/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Fortress Biotech NASDAQ:FBIO$1.69 -0.03 (-1.74%) Closing price 05/8/2025 03:59 PM EasternExtended Trading$1.71 +0.02 (+1.42%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Regulus Therapeutics NASDAQ:RGLS$7.85 0.00 (0.00%) Closing price 05/8/2025 04:00 PM EasternExtended Trading$7.84 0.00 (-0.06%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Verastem NASDAQ:VSTM$6.94 +0.25 (+3.74%) Closing price 05/8/2025 04:00 PM EasternExtended Trading$7.26 +0.32 (+4.54%) As of 06:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
